Press Releases
-
Apr 29, 2020
- U.S. Marketing Application for Valoctocogene Roxaparvovec for Severe Hemophilia A Accepted by FDA under Priority Review with Prescription Drug User Fee Act (PDUFA) action date of August 21, 2020Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended March 31, 2020 2019 % Change Total Revenues $ 502.1 $ 400.7 25 % Net Product Revenues...
-
Apr 22, 2020
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday,...
-
Apr 21, 2020Robert Baffi, Ph.D., President, Global Manufacturing and Technical Operations Moves Toward Retirement and Continues in Full-Time Capacity as Special Advisor to the Chairman and CEO During Transition Before Retiring
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced the appointment of C. Greg Guyer, Ph.D., to Chief Technical Officer, Executive Vice President of Global Manufacturing and Technical...
-
Apr 14, 2020
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday,...
-
Apr 6, 2020If approved, vosoritide would be the first medicine for the treatment of Achondroplasia in the US and EU
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that based on recent meetings with health authorities in the US and Europe, the Company plans to submit marketing applications to the US...
